BCRX
Price
$8.07
Change
-$0.12 (-1.47%)
Updated
Sep 9, 04:59 PM (EDT)
Capitalization
1.72B
50 days until earnings call
CUE
Price
$0.77
Change
-$0.01 (-1.28%)
Updated
Sep 9, 04:37 PM (EDT)
Capitalization
60.15M
58 days until earnings call
Interact to see
Advertisement

BCRX vs CUE

Header iconBCRX vs CUE Comparison
Open Charts BCRX vs CUEBanner chart's image
BioCryst Pharmaceuticals
Price$8.07
Change-$0.12 (-1.47%)
Volume$49.91K
Capitalization1.72B
Cue Biopharma
Price$0.77
Change-$0.01 (-1.28%)
Volume$130
Capitalization60.15M
BCRX vs CUE Comparison Chart in %
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Illumina (NASDAQ:ILMN), Exact Sciences Corp (NASDAQ:EXAS), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA).

Industry description

Few industries pique investor interest like the high-risk, high-reward biotechnology sector. It is not unusual for a biotech company’s stock to soar in value following the development of a successful product...even if it is just as likely that tens of millions of dollars in research will lead to nothing substantial. Biotech companies earn headlines for developing lifesaving and (potentially) massively lucrative treatments for illness, but the industry’s scope extends beyond healthcare to food and agriculture, industrial processing, and more. Any company producing technology that incorporates biological organisms falls within the sector. The search for the next big thing in biotech may come with risk, but investors have reason for optimism. Biotech products like DNA sequencing and gene therapy are experiencing increased demand and decreasing prices, while rising populations around the world mean demand for food and agricultural products resistant to environmental factors. Biotech’s biggest names include multinational corporations like Johnson & Johnson, Amgen, and Roche, who each sport market capitalizations in the hundreds of billions of dollars. With new government rules opening China as a market for new treatments, the biotech sector holds significant growth potential – and corresponding profitability for investors.

Market Cap

The average market capitalization across the biotechnology Theme is 6.87B. The market cap for tickers in the group ranges from 658 to 184.14B. TMO holds the highest valuation in this group at 184.14B. The lowest valued company is MTEM at 658.

High and low price notable news

The average weekly price growth across all stocks in the biotechnology Theme was 2%. For the same Theme, the average monthly price growth was 15%, and the average quarterly price growth was 47%. NBY experienced the highest price growth at 52%, while ADAP experienced the biggest fall at -28%.

Volume

The average weekly volume growth across all stocks in the biotechnology Theme was 17%. For the same stocks of the Theme, the average monthly volume growth was -6% and the average quarterly volume growth was -12%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 76
Price Growth Rating: 53
SMR Rating: 87
Profit Risk Rating: 89
Seasonality Score: -25 (-100 ... +100)

Notable companies

The most notable companies in this group are BioCryst Pharmaceuticals (NASDAQ:BCRX).

Market Cap

The average market capitalization across the group is 889.7M. The market cap for tickers in the group ranges from 60.15M to 1.72B. BCRX holds the highest valuation in this group at 1.72B. The lowest valued company is CUE at 60.15M.

High and low price notable news

The average weekly price growth across all stocks in the group was -1%. For the same group, the average monthly price growth was -4%, and the average quarterly price growth was -8%. CUE experienced the highest price growth at 0%, while BCRX experienced the biggest fall at -1%.

Volume

The average weekly volume growth across all stocks in the group was 1%. For the same stocks of the group, the average monthly volume growth was -19% and the average quarterly volume growth was -46%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 33
P/E Growth Rating: 100
Price Growth Rating: 58
SMR Rating: 100
Profit Risk Rating: 89
Seasonality Score: 0 (-100 ... +100)
VS
BCRX vs. CUE commentary
Sep 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and CUE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 09, 2025
Stock price -- (BCRX: $8.19 vs. CUE: $0.78)
Brand notoriety: BCRX: Notable vs. CUE: Not notable
BCRX represents the Pharmaceuticals: Generic, while CUE is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 64% vs. CUE: 33%
Market capitalization -- BCRX: $1.72B vs. CUE: $60.15M
BCRX [@Pharmaceuticals: Generic] is valued at $1.72B. CUE’s [@Biotechnology] market capitalization is $60.15M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.25B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $101.34B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.98B. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileCUE’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • CUE’s FA Score: 0 green, 5 red.
According to our system of comparison, both BCRX and CUE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 4 TA indicator(s) are bullish while CUE’s TA Score has 2 bullish TA indicator(s).

  • BCRX’s TA Score: 4 bullish, 4 bearish.
  • CUE’s TA Score: 2 bullish, 3 bearish.
According to our system of comparison, BCRX is a better buy in the short-term than CUE.

Price Growth

BCRX (@Pharmaceuticals: Generic) experienced а -1.44% price change this week, while CUE (@Biotechnology) price change was +0.33% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.50%. For the same industry, the average monthly price growth was +10.21%, and the average quarterly price growth was +52.06%.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.23%. For the same industry, the average monthly price growth was +11.73%, and the average quarterly price growth was +36.34%.

Reported Earning Dates

BCRX is expected to report earnings on Oct 29, 2025.

CUE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.50% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (+2.23% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCRX($1.72B) has a higher market cap than CUE($60.2M). BCRX YTD gains are higher at: 8.910 vs. CUE (-28.183). BCRX has higher annual earnings (EBITDA): 63.4M vs. CUE (-36.07M). BCRX has more cash in the bank: 260M vs. CUE (27.5M). CUE has less debt than BCRX: CUE (7.63M) vs BCRX (703M). BCRX has higher revenues than CUE: BCRX (558M) vs CUE (8.29M).
BCRXCUEBCRX / CUE
Capitalization1.72B60.2M2,855%
EBITDA63.4M-36.07M-176%
Gain YTD8.910-28.183-32%
P/E RatioN/AN/A-
Revenue558M8.29M6,734%
Total Cash260M27.5M945%
Total Debt703M7.63M9,209%
FUNDAMENTALS RATINGS
BCRX vs CUE: Fundamental Ratings
BCRX
CUE
OUTLOOK RATING
1..100
5867
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
34
Fair valued
PROFIT vs RISK RATING
1..100
78100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6354
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (32) in the Biotechnology industry is in the same range as CUE (34). This means that BCRX’s stock grew similarly to CUE’s over the last 12 months.

BCRX's Profit vs Risk Rating (78) in the Biotechnology industry is in the same range as CUE (100). This means that BCRX’s stock grew similarly to CUE’s over the last 12 months.

BCRX's SMR Rating (100) in the Biotechnology industry is in the same range as CUE (100). This means that BCRX’s stock grew similarly to CUE’s over the last 12 months.

CUE's Price Growth Rating (54) in the Biotechnology industry is in the same range as BCRX (63). This means that CUE’s stock grew similarly to BCRX’s over the last 12 months.

CUE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BCRX (100). This means that CUE’s stock grew similarly to BCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXCUE
RSI
ODDS (%)
Bullish Trend 6 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
70%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 28 days ago
79%
Bullish Trend 19 days ago
79%
Declines
ODDS (%)
Bearish Trend 8 days ago
79%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
78%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HYTLF0.02N/A
+6.67%
HYTERRA LTD.
PXMBF3.50N/A
N/A
PAXMAN AB
IMYSY5.50N/A
N/A
IMERYS SA
DNQUF10.42N/A
N/A
Denali Capital Acquisition Corp.
CRRFY2.92-0.01
-0.34%
Carrefour S.A.

BCRX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
-0.97%
VCYT - BCRX
46%
Loosely correlated
+0.12%
CRNX - BCRX
42%
Loosely correlated
-1.32%
HOWL - BCRX
39%
Loosely correlated
-2.22%
ROIV - BCRX
38%
Loosely correlated
N/A
BEAM - BCRX
38%
Loosely correlated
-4.50%
More

CUE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CUE has been loosely correlated with DNLI. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CUE jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CUE
1D Price
Change %
CUE100%
+0.36%
DNLI - CUE
39%
Loosely correlated
+0.52%
VCYT - CUE
36%
Loosely correlated
+0.12%
OCS - CUE
36%
Loosely correlated
+0.17%
INAB - CUE
35%
Loosely correlated
-0.23%
SGMT - CUE
33%
Loosely correlated
-1.13%
More